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Introduction: Although binge eating disorder (BED) is an eating disorder and obesity is a
clinical disease, it is known that both conditions present overlapped symptoms related to,
at least partially, the disruption of homeostatic and hedonistic eating behavior pathways.
Therefore, the understanding of neural substrates, such as the motor cortex excitability
assessed by transcranial magnetic stimulation (TMS), might provide new insights into the
pathophysiology of BED and obesity.
Objectives: (i) To compare, among BED, obesity, ex-obese, and HC (healthy control)
subjects, the cortical excitability indexed by TMS measures, such as CSP (cortical silent
period; primary outcome), SICI (intracortical inhibition), and ICF (intracortical facilitation;
secondary outcome). (ii) To explore the relationship of the CSP, eating behavior (e.g.,
restraint, disinhibition, and hunger), depressive symptoms, and sleep quality among the
four groups (BED, obesity, ex-obese, and HC).
Methods: Fifty-nine women [BED (n = 13), obese (n = 20), ex-obese (n = 12), and
HC (n = 14)] comprise the total sample for this study. Assessments: cortical excitability
measures (CSP, SICI, and ICF), inhibition response task by the Go/No-go paradigm, and
instruments to assess the eating psychopathology (Three-Factor Eating Questionnaire,
Eating Disorder Examination Questionnaire, and Binge Eating Scale) were used.
Results: A MANCOVA analysis revealed that the mean of CSP was longer in the BED
group compared with other three groups: 24.10% longer than the obesity group, 25.98%
longer than the HC group, and 25.41% longer than the ex-obese group. Pearson’s
correlations evidenced that CSP was positively associated with both eating concern and
binge eating scores.
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Conclusion: The findings point out that BED patients present longer CSP, which
might suggest an upregulation of intracortical inhibition. Additionally, CSP was positively
correlated with Binge Eating Scale and eating concern scores. Further studies
are needed.
Keywords: binge-eating disorder, obesity, cortical excitability, eating behavior, executive function, eating disorders
INTRODUCTION
Binge eating disorder (BED) is characterized by the consumption
of large amounts of food associated with an experienced loss of
control (1). Although BED is a psychiatric disorder and obesity
is a medical condition, both present overlapped symptoms
related to, at least somehow, the disruption of homeostatic
and hedonistic eating behavior pathways (2). According to
studies that used behavioral, neurobiological, and neuroimage
techniques, the overeating habit is associated with top-down
psychological processes, such as disinhibition, impulsivity, and
risk-taking propensity (3). Obese individuals with BED show
increased impulsivity (rash-spontaneous behavior) compared to
obese without BED and normal-weight individuals, in general
or in food-specific tasks that can denote a distinct phenotype
within the obesity spectrum (4). Corroborating these findings,
neuroimage data revealed that BED and obesity showed some
abnormal patterns in the frontal region of the brain, as well
as the mesocorticolimbic circuits involved in reward processing
and decision-making (5, 6). These dysfunctions indicate that
neuroplastic networks mediate the equipoise in reward neural
networks, and the homeostatic system stands out as a possible
shared mechanism between these two conditions (7). Studies
performed in BED and/or in obese subjects found impaired
executive control compared to healthy controls (HC) (8). BED
patients have displayed stronger inhibitory deficits on the
Go/No-go task compared with obese individuals (4, 9). On the
other hand, in both BED (10) and obesity (11), a diminished
ability to inhibit responses related to food on the Go/No-go
task compared with lean controls has been evidenced. These
data suggest that the poor decision-making and the uncontrolled
impulse may be facilitated, having as a consequence overeating in
both groups.
Impulse control involves several neurobiological systems,
such as dopaminergic, gamma-aminobutyric acid (GABA-ergic),
glutamatergic, serotonergic, etc. (12). Whereas the neuronal
circuits involved in the hedonic order are in the corticolimbic
order, and their signaling methods include dopaminergic
and opioid pathways (12), in this circuitry, the GABAergic
interneurons contribute to the disinhibitory control of reward-
related response (12). In subcortical regions, the basal ganglia,
such as the nucleus accumbens (NAc) has GABA-containing
cells, with projections to thalamus, midbrain, and brainstem (12).
Thereby, inhibitory circuits can lead to maladaptive behavioral
changes, such as overeating (13). In particular, inhibitory synaptic
plasticity within the mesocorticolimbic system alters circuit
function and mediates behavioral adaptations related to stress
(13). In this pathway, the dopaminergic neurons received
GABAergic inputs from other neural networks and GABA
inhibits mesolimbic dopamine signaling in the ventral tegmental
area (VTA) (12). Thus, the dysfunction in the inhibitory neural
networks emerges as a possible mechanism underlying eating
disorders and comprises the rationale to use neuromodulatory
techniques as a therapeutic option [e.g., transcranial magnetic
stimulation (TMS)] as recently proposed by Stramba-Badiale
et al. (6).
Neuromodulatory techniques, such as TMS, have been
utilized not only as a diagnostic tool to access cortical
excitability of a target brain region, being an indirect
measure of the activity of GABA receptors, but also as
treatment strategies [repetitive TMS (rTMS)] for a variety
of neurologic and psychiatric disorders. Administration of
single or multiple sessions of rTMS over right and/or left
dorsolateral prefrontal cortex (DLPFC) showed reduction
in craving, weight, and eating disorder (ED) symptoms
(6, 14, 15).
Thereby, it is reasonable to consider the motor cortex
excitability measured by TMS as probing neural plasticity
indexes to improve the comprehension of the neural substrates
shared by BED and obesity, as well as their interplay
with measures of impulsivity, and with impulse control by
behavioral paradigms, such as the Go/No-go. Thus, this
study tested the hypothesis that BED patients would present
higher disinhibition of the motor cortex compared to obese,
ex-obese, and HC subjects. The aims of this study were
the following: (i) To compare, among subjects with BED,
obesity, ex-obese, and HC, the cortical excitability indexed
by TMS measures, such as CSP (cortical silent period;
primary outcome), SICI (intracortical inhibition), and ICF
(intracortical facilitation; secondary outcome). (ii) To explore
the relationship of the CSP, eating behavior (e.g., restraint,
disinhibition, and hunger), depressive symptoms, and sleep
quality among the four groups (BED, obesity, ex-obese,
and HC).
METHODS AND MATERIALS
Study Design, Settings, and Subjects
The researchers conducted a cross-sectional study
following the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement. The
Ethics Committee Board of the Hospital de Clínicas de
Porto Alegre (HCPA) (Institutional Review Board IRB
70321817900005327) approved the protocol. All subjects
provided oral and written consent before their engagement in
the study.
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Participants
Volunteers were outpatients from primary health care units or
psychiatric outpatient clinics and tertiary hospitals (obese and
BED groups, respectively), enlisted from the local community by
advertisement postings in universities and public places in Porto
Alegre, Brazil. The sample included literate, female, self-reported
right-handed, 18- to 65-year-old subjects. The common exclusion
criteria were formal contraindication for TMS (e.g., pregnancy,
history or diagnostic of seizure, metal implants in the head, etc.),
history of alcohol abuse or other drugs in the past 6 months,
individuals undergoing weight loss treatment, bariatric surgery
individuals, and night shift workers.
Obese and lean individuals were diagnosed according to
World Health Organization (WHO) criteria (BMI> 29.99 kg/m2
and between 18.5 and 24.99 kg/m2, respectively). Volunteers
classified as lean, according to BMI, at the time of the interviews
and who had a clinical history of obesity (BMI > 29.99 kg/m2)
at least 6 months before the study, according to medical or
nutritional records, were assigned to the Ex-obese group.
Diagnosis of BED was performed according to the diagnostic
criteria outlined in the Diagnostic And Statistical Manual Of
Mental Disorders, 5th Edition (1), applied by a trained mental
health professional. Lean individuals (HC and Ex-obese group)
were excluded if any eating disorder diagnosis were confirmed.
Obese individuals were included in the BED group if BED
diagnosis was confirmed and excluded if any other eating
disorder was diagnosed.
In addition, to assure that HC did not present any kind of
impulsivity behavior, we applied the settled cutoffs to the Barratt
Impulsiveness Scale (BIS-11) (16), the South Oaks Gambling
Screen (SOGS) (17), and The Richmond Compulsive Buying
Scale (RCBS) (18) as exclusion criteria. The inclusion and
exclusion criteria pertaining to each one of the four groups
(obese, BED, ex-obese, and HC) are detailed in Figure 1.
Instruments and Assessment
Outcomes
The primary outcome was the motor cortex inhibitory function
indexed by CSP. Secondary outcomes were SICI, ICF, response
inhibition through the Go/No-go paradigm, and eating
psychopathology by standardized questionnaires [Three-Factor
Eating Questionnaire (TFEQ), Eating Disorder Examination
Questionnaire (EDE-Q), and Binge Eating Scale (BES)].
Dependent Variables
Cortical Excitability Measures
(a) TMS measures: The researchers used a MagProX100
stimulator with a figure-eight coil (MagVenture Company,
Lucernemarken, Denmark) to access cortical excitability on
the left primary motor cortex (M1). Subjects were placed in
a comfortable chair and informed about all the procedures,
including possible sensations that might be experienced during
TMS measures. Surface electromyography (EMG) electrodes
were placed on the right first dorsal interosseous (FDI) muscle
and its tendon. Each participant had their hot spot identified on
left M1 positioning the coil at a 45◦ angle to the sagittal line
tangential to the scalp, marking the individual site with a soft-
tipped pen. The same researcher performed all TMS assessments
to reduce variability. The following parameters were used to settle
the TMS measures:
-Motor threshold (MT): MT was obtained at rest (rMT), and
it is a measure that reflects the excitability of the membrane
potential of pyramidal neurons in M1 (19), and it is defined as
the lowest stimulus needed to induce 50% of the FDI muscle-
evoked potentials (MEPs). To settle MT measure, the minimum
amplitude of 50 µV in 5 of 10 successive trials was performed,
followed by single-pulse TMS with an intensity of 130% of MT to
record 10 MEPs (20).
-CSP: CSP has been associated with an inhibitory network
influenced by GABA-B receptors (21). CSP was recorded in
milliseconds (ms) using an intensity of 130% of MT during FDI
muscle activity measured on a dynamometer set to ∼20% of
the maximal force (22). The average of 10 sequential measures
of MEP/CSP-rectified traces was then recorded, which makes it
possible to visualize the voluntary EMG activity level at baseline
(i.e., prior to the TMS pulse). Thus, the cessation of the CSP can
be demarcated more precisely by the return of voluntary EMG
activity relative to the tonic baseline EMG level, as the second
method described by Rossini (20, 23).
-SIC and ICF: SICI mainly reflects GABA-A receptor-
mediated inhibitory function (24, 25), while ICF denotes
excitability of excitatory neuronal circuits in motor cortex, which
are at least in part dissociable from the SICI network (26)
and mostly mediated through the glutamatergic N-methyl-D-
aspartate receptor (NMDA) (27), according to pharmacological
experiments (26). It is conceivable that ICF is a net facilitation
mainly comprising facilitation and weaker inhibition (28).
The TMS protocol to measure SICI and ICF used a total of
30 randomized paired-pulse trials, 10 for each measure (SICI,
ICF, and control stimuli) with an interstimulus interval (ISI) to
evaluate the SICI equal to 2 and 12ms for ICF, respectively. The
first individual conditioning stimulus was set at 80% of the MT,
while the test stimulus was set at 130% (29, 30).
(b) Go/No-go paradigm: It was performed to assess the
response inhibition, the secondary outcome component of
cognitive control in this study. The neutral and food-based
Go/No-go tasks were designed and run using E-PrimeTM software
(Psychology Software Tools, Inc., Sharpsburg, PA, USA) by a
psychologist. The images selected to compose the stimuli in this
experiment were gathered from the Bank of Standardized Stimuli
(BOSS), a free standardized set of visual stimuli, consisting
of a normative database organized by category, familiarity,
visual complexity, object agreement, and viewpoint agreement,
and therefore, equivalent in both valence and perceptual
characteristics (31). In the neutral-based task, the target (Go)
stimulus was the toiletries images, while the non-target (No-
go) stimulus was the images of sports equipment. In the food-
based task, the target (Go) stimulus was images of neutral office
supplies, while the non-target (No-go) stimulus was the images
of high-fat and/or high-sugar foods. Distinct target image (Go)
stimulus was selected to neutral and food tasks, to reduce the
likelihood of an inductive bias due to a learning algorithm related
to repetitive practice effects (Figure 2).
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FIGURE 1 | Flow of the study.
All stimuli were displayed in the center of a computer screen
for 500 ms/each. The ISI is 1,000ms (trial length = 1,500ms).
A fixation cross was displayed in the center of the screen during
the ISI. Subjects were instructed to continuously verify a series of
stimuli presented individually centered on the computer screen.
They had to answer as fast as possible by pressing the keyboard
space bar whenever a target (Go) stimulus was presented (80%
of trials) and not answer to an infrequently presented not target
[No-go stimulus (20% of trials)]. The presentation order was
fully counterbalanced. Themeasure of interest was the number of
commission errors (the number of incorrect answers performed
during the No-go trials) (11). The entire task consisted of 200
trials divided into two 100 trial runs and the last 750 ms each.
Assessment of Eating Psychopathology
(c) Eating behavior psychopathology:
-TFEQ: It covers three eating-related concepts: dietary
restraint, disinhibition, and susceptibility to hunger (32). It is
a well-rated measure in which the dietary restraint refers to
the tendency to consciously restrict food intake as a means
of controlling weight, the disinhibition refers to a tendency to
overeat in response to negative emotional states or the presence
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FIGURE 2 | The Go/No-go paradigm. (A) Neutral task, (B) Food task. Each task had 100 trials divided in two blocks of 50. A total of 200 trials were presented
(Neutral + Food). Images were presented using a ratio of 80% “go” to 20% “no-go” trials to create a prepotent “go” response. Each trial was presented for 750 ms
and was separated by a blank screen for 500 ms and preceded by a fixation point for 500 ms. The go and no-go categories were presented in a pseudorandomized
order, with 3, 4 or 5 go trials in between every no-go trials. Presentation order of the food and neutral tasks was fully counterbalanced.
of highly palatable foods, and the hunger subscale assesses
susceptibility to feelings of hunger.
-EDE-Q: It is a 28-item composed of four subscales and
a global score that reflects the severity of eating disorder
psychopathology (33).
-BES: It consists of a 16-item Likert scale, in which eight
of them describe the behavioral manifestations and the others
describe the feelings and cognition related to the binge eating
episodes. A translated, adapted, and certified version in Brazilian
Portuguese was applied to assess the severity of the binge eating
episodes (34). The scores range from 0 to 46. A cutoff of equal to
or >18 indicates the presence of binge eating.
(d) Measures of hunger, satiety, and appetite: According to
a previous protocol designed by Jauch-Chara et al. (35), we
provided a 10-point numerical rating scale [from 0 (any desire
or need regard eating) to 10 (very prominent desire or need
regard eating)] in which the subjects should score their hunger,
feeling of hunger, satiety, and appetite to specific (sweet and
savory food) and unspecific food in the last 24 h before the study
assessment (35).
(e) Standardized questionnaire: it was used to assess
demographic and medical data. Patients were requested to
provide information about their age, sex, level of education,
marital status, and lifestyle habits. They also provided
information about their health status, including clinical
and psychiatric diagnosis.
Independent Variables
Anthropometry, Psychological, Demographic, and
Clinical Characteristics
Anthropometric measures
Height was measured in centimeters (cm) using a height scale
(Sanny, 14024) with the subject standing bare feet and with
a normal straight posture. Weight was measured in kilograms
(kg) using a weight scale (Toledo, 2096 PP). Obese and lean
individuals were diagnosed according to the WHO criteria (BMI
> 29.99 kg/m2 and between 18.5 and 24.99 kg/m2, respectively).
Psychiatric diagnosis
It was based on the Structured Clinical Interview for DSM-V
(SCID) applied by two independent trained psychiatrists. This
instrument consists of a semi-structured diagnostic interview
created from DSM-V. The answers identify the presence or
absence of the symptoms, scored according to the judgment
of the reviewer. It is composed of 10 modules, which can
be used in a combined or independent way (2012). In the
study, the “A” module was used to diagnose mood episodes
(major depressive disorders). The translation and adaptation of
this clinical interview into the Portuguese language present, in
general, good reliability for mood disorders (36).
Psychological state and sleep quality
All instruments used were validated for the Brazilian population
and the assessments were conducted by two trained reviewers.
The following tools were applied: Beck Depression Inventory-II
(BDI-II) (37), Pittsburgh Sleep Quality Index (PSQI) (38), and
State-Trait Anxiety Inventory (STAI) (39).
Demographic and clinical characteristics
Subjects were asked about current and previous (6 months
prior to the study) use of psychotropic drugs. Licit and
illicit psychotropic drugs were assessed by a standardized
questionnaire, which also includes medical comorbidities and
demographic data. Participants in both HC and Ex-obese groups
were carefully screened to be drug-naive. Besides, they were
taught not to take any medication, caffeine, or any stimulant
drinks at least 6 h prior to the TMS assessment. Subjects from the
BED and Obese groups, due to ethical issues, were instructed to
sustain their prescribed medicines and they were, as well, taught
not to take any additional medications, caffeine, or any stimulant
drinks at least 6 h prior to the TMS assessment.
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Efforts to Address Potential Sources of Bias
In order to reduce assessment bias, a trained researcher
applied the psychiatric diagnosis based on the SCID-V and the
instruments about eating behavior and clinical and demographic
characteristics. To reduce the variability, the same researcher
performed all TMS and Go/No-go task assessments.
Study Size
A sample size of 60 participants were estimated for type I and type
II errors of 0.05 and 0.20, respectively, and anticipating partial
η
2 of 0.25 for multiple regression analysis, which allows for two
predictors (the group of eating disorder and use of psychotropics
medication). It was calculated using the post-hoc statistical power
calculator for hierarchical multiple regression at https://www.
danielsoper.com/statcalc/calculator.aspx?id=17.
Statistical Analysis
Shapiro–Wilk’s test was performed to test normality. Descriptive
statistics were used to summarize the main characteristics of the
sample. ANOVA was performed to compare the four groups in
the univariate analysis regarding cortical excitability and eating
disorder psychopathology. MANCOVA was used to test the
differences between groups (BED, obese, ex-obese, and HC) on
the multiple outcomes controlled for psychotropic drugs. The
dependent variables included in the MANCOVA were cortical
excitability (CSP, SICI, and ICF), inhibitory control, and eating
behavior (secondary outcomes).
Commission errors on “No-go” trials in the neutral-based
Go/No-go task served as the gold standard for behavioral
inhibition in these analyses. Performance differences on the
neutral vs. food Go/No-go tasks were analyzed through GLM.
To analyze the correlation between the CSP, eating behavior,
and the Go/No-Go task, Pearson’s correlation analysis was used.
All analyses were adjusted by multiple comparisons using the
Bonferroni’s multiple comparison test. To analyze the data, we
used the software SPSS version 22.0 (SPSS, Chicago, IL, USA).
Statistical significance was set at the 0.05 level for all analyses.
RESULTS
Socio-Demographic, Clinical, and
Psychological Characteristics of the
Sample
Demographic, clinical, and psychiatric characteristics are
summarized in Table 1. Univariate analysis evidenced that the
BED group presented poor quality sleep compared to the HC
and ex-obese groups. Subjects with BED showed higher levels of
depressive symptoms compared to the other three groups.
Univariate Analysis
Assessment of Cortical Excitability According to
Groups
The cortical excitability parameters measured by TMS according
to eating disorder group are presented in Table 2. It was observed
that the BED group compared to obese, ex-obese, and HC
displayed larger CSP (F = 2.359; P = 0.031). There were
no significant differences among groups in the other cortical
excitability measures (SICI and ICF).
Multivariate Analysis—Primary Outcome
Cortical Excitability Measures According to Eating
Disorder Diagnosis
A MANCOVA model that was constructed with the cortical
excitability parameters (SICI, ICF, and CSP) as dependent
variables, eating disorders (factor) as independent variables, and
the use of psychotropic medications as a covariate is presented in
Table 3. The analysis revealed a significant difference between the
groups (Hotelling’s Trace= 0.64, F= 2.436, P= 0.007). The BED
group presented higher CSP than the three other groups. The use




Assessment of the Relationship Between CSP and
Response Inhibition Through the Go/No-Go
Paradigm With Eating Behavior Psychopathology
According to the Groups
A MANCOVA model, with the cortical silent period (primary
outcome), Go/No-Go paradigm (commission errors from neutral
and food task), and Eating Behavior (EDE-Q global score and
BES) as dependent variables, was used. The BED group presented
higher CSP than the other three groups. Also, the BED group
presented higher scores in the BES than the other three groups,
which was positively influenced by the BDI-II (score). The HC
group presented a lower global score in EDE-Q than the other
groups, and this finding was negatively correlated with depressive
symptoms assessed through BDI-II. However, we did not find
differences between groups in the Go/No-Go task.
Exploratory Analysis
Correlation Among CSP, Eating Behavior, Depressive
Symptoms, and Sleep Quality
Pearson’s correlation analysis coefficients among CSP, eating
behavior, and inhibitory control through the Go/No-Go
paradigm area are presented in Table 4. The CSP was positively
correlated with BES (r = 0.34, P < 0.01), Eating Concern (r =
0.26, P < 0.05), and BDI-II (r = 0.30, P < 0.05), while the BES
was positively correlated to BDI-II (r = 0.70, P < 0.01) and PSQI
(r = 0.54, P < 0.01). BDI-II was positively associated with the
EDE-Q global score (r = 0.71, P < 0.01) (Figure 3).
DISCUSSION
The innovation of these findings is to indicate that BED may
be associated with a dysfunction in the GABAergic system
as indicated by a longer CSP in this group compared to the
other three. This finding is relevant in a physiological field,
and it may be clinically relevant to investigate new therapeutic
strategies in BED, mainly because it is one of the latest
eating disorders formally recognized in the DSM-5 (1). This
finding is supported by earlier studies that revealed that the
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Age (years) 31 (±7.25) 26.42 (±4.27) 30.91 (±7.66) 32.17 (±7.85) 0.173
BMIc (kg/m2) 33.05 (±3.99)b 33.15 (±3.74)b 23.41 (±1.62)a 21.33 (±1.98)a <0.001
Obesity I 14 8 – – –
Obesity II 3 3 – – –
Obesity III 3 1 – – –
Years of education 14.68 (±3.42) 15.04 (±3.24) 16.88 (±5.63) 16.53 (±2.56) 0.295
Employed (yes/no) 20/0 13/0 12/0 14/1 –
Alcohol use (yes/no) 13/7 9/4 9/3 14/1 –
Clinical and psychiatric
Use of psychotropic medication
Selective serotonin reuptake inhibition
SSRTIs (yes/no)
3/17 7/6 0/0 0/0 –
Other antidepressants (yes/no) 1/19 5/10 0/0 0/0 –
Psychiatric disorder according to the
SCID-V
Major depressive episode 2/18 5/13 0/0 0/0 –
Bipolar disorder 1/19 1/13 0/0 0/0 –
Generalized anxiety disorder 5/15 8/13 2/12 0/0 –
Panic disorder 0/0 2/13 0/0 0/0 –
Attention deficit hyperactivity disorder 1/19 1/13 0/0 0/0 –
Beck Depression Inventory—BDI-II 10.15 (±8.45)a 25.15 (±11.02)b 11.08 (±9.85)a 8.44 (±7.60)a <0.001
BDI-II (score > 10) 8 12 5 –
State-Trait Anxiety Inventory
STAI—State 22.75 (±6.48) 28.38 (±8.95) 25.0 (±12.84) 29.6 (±9.73) 0.146
STAI—Trait 21.05 (±4.47) 25.0 (±3.93) 23.41 (±4.92) 22.46 (±5.18) 0.123
Pittsburgh Sleep Quality Index (PSQI) 11.05 (±7.44)a,b 17.07 (±8.56)b 8.83 (±4.52)a 8.20 (±4.49)a 0.004
Poor Sleep—PSQI (score > 5) 15 12 10 9
Binge Eating Scale 10.50 (±5.23)a 23.38 (±5.70)b 10.91(±7.94)a 7.07(±5.40)a <0.001
International Physical Activity
Questionnaire (MET)
4,407.15 (±4,768.80) 1,801.92 (±2,321.67) 6,604.66 (±8,337.37) 4,678.85 (±4,955.10) 0.177
Data are presented as average and standard deviation (n = 59).
cBody mass index. Comparisons using ANOVA. Post-hoc differences among groups are indicated via superscript letters.
CSP is an index of intracortical inhibition, as shown in a
previous study that assessed the GABAB inhibition processes
(21). We hypothesized that the mechanisms underlying the CSP
could participate in the generation of surround inhibition and
disengage pathways involved in the eating control. Although
underpinning mechanisms of our results related to longer CSP
in BED are not clear, according to earlier studies, the CSP
reflects the inhibitory activity in the M1 (40–42), which is
modulated by several cortical and subcortical systems (43). Our
hypothesis that BED is associated with an amplified GABAB-
mediated inhibitory activity in the primary motor cortex (M1) is
supported by pharmacological studies with IV selective GABAB
agonist baclofen, which revealed the augmentation of CSP length
followed its infusion (44).
It is thought that GABABR signaling in themesolimbic system
regulates hedonic food consumption, whereas the hypothalamic
neurons play an essential role in the homeostatic regulation of
energy balance. Based on this rationale, experimental (45, 46) and
clinical (47, 48) data have confirmed the effectiveness of baclofen
in the reduction of binge eating. Regarding mechanism, baclofen
acts on presynaptic GABAB receptors by modulating G-protein-
gated inwardly rectifying potassium (GIRK/Kir3) channels to
inhibit cortico-mesolimbic dopamine neurotransmission (49).
Therefore, we hypothesize that the augmented GABAB
activity, indexed by prolonged CSP, found in BED individuals
could reflect the enhancement of certain inhibitory phenomena
in patients with this disorder. Indeed, they presented a
modified balance between excitability and inhibition of
neural networks, which chronically shifts toward the overt
hyperexcitability. This assumption can be consistent with
the loss of control overeating. Following in this line, our
findings are supported by cumulative evidence in epilepsy
research that also verified a robust amplification of the CSP
in untreated patients with generalized and partial epilepsies
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Motor threshold—MT (%) 44.5 (±6.9) 47.0 (±5.3) 47.8 (±5.0) 45.5 (±7.7) 0.571 0.637
Motor evocate potential—MEP (mV) 335.85 (±371.78) 693.62 (±1,083.13) 853.75 (±593.62) 584.55 (±710.90) 1.444 0.202
Intracortical Facilitation—ICF (mV) 1.45 (±2.29) 1.72 (±1.95) 2.28 (±1.88) 1.65 (±1.34) 0.489 0.858
Short Intracortical Inhibition—SICI (mV) 1.04 (±2.18) 0.64 (±0.69) 0.45 (±0.42) 0.22 (±0.22) 0.662 0.722
Cortical Silent Period—CSP (ms) 95.21 (±15.76)a 118.16 (±17.75)b 94.22 (±20.82)a 93.79 (±27.30)a 2.350 0.031
Data are presented as average and standard deviation (n = 59). Different superscripts (a, b) indicate significance. To compare means, the analysis of variance (ANOVA) was used.
Difference among groups after post hoc analysis adjusted by Bonferroni (P < 0.05).
when compared to HC (50, 51). Hence, our results, as well
as previous epilepsy research, point out that the large CSP
might designate a hyperactivation of inhibitory neural circuits.
Besides, it is conceivable that the higher CSP length in BED
individuals displays hyperexcitability of inhibitory circuits as a
consequence of unsuitable neuroplastic changes in the attempt
to restore homeostasis.
Interestingly, the role of GABABR in corticostriatal neurons
has been explored in a knockout (KO) model, which revealed
the increase in binge-like feeding of high-fat diet (HFD),
while the administration of baclofen was able to suppress
it presumably via the mesolimbic pathway. In addition, they
have shown that GABABR signaling in the mesolimbic system
does not affect energy balance, concluding that the mesolimbic
system regulates binge-like eating of HFD and providing
a mechanism by which the GABABR signaling suppresses
palatable food consumption (52). However, it is essential to
emphasize that GABABRs were also knocked out in mPFC
and OFC, which are known critical areas in decision-making
(53) and, therefore, could also be implicated in this binge
eating model. Notwithstanding, it remains unclear which
neurotransmitter is critical for GABABR signaling to suppress
binge eating behavior.
In line with the abnormal cortical excitability in the BED
group, CSP was correlated with scores of BES and EDE-
Q. Eating behavior assessed by the BES and EDE-Q was
correlated with the BDI-II. Psychiatric comorbidity rates
are significantly higher among obese individuals with BED
compared to those without BED (1), and psychiatric comorbidity
is linked to the severity of binge eating (1). Indeed, comorbid
depressive symptoms in individuals with BED have been
correlated with greater traits of impulsivity and sensitivity to
punishment (54). Taken together, the high comorbidity between
BED and MDD might be explained through abnormalities
found in the dopaminergic and serotonergic function,
which strengthens the comorbidity differences compared
to those obese individuals without BED diagnosis (55–57).
Besides, eating disorders such as BED are associated with
more reduced sleep quality and, notably, worsening binge
eating (58).
Contrary to our hypothesis, we have not found inhibitory
control deficits in response to high-calorie foods in the
Go/No-go task among the groups. Obesity and BED partake
a disruption in the executive function related to impulsivity,
which is not entirely supported by previous research (59). A
neuroimaging study found reduced activation in the prefrontal
cortex (inferior frontal gyrus, ventromedial prefrontal cortex,
and dorsolateral prefrontal cortex) during an inhibitory control
task in obese participants compared to the control task on
lean participants and there were no differences in inhibitory
control performance task (5, 60), suggesting that obese
individuals might have difficulty in maintaining inhibitory
control, rather than a general impairment, and the maintenance
also depends on external factors like motivation state (61).
It is important to emphasize that the performance in tasks
assessing inhibitory control, especially those addressed by
food-associated tasks, is inconsistent since negative results in
inhibitory control deficits have been previously reported (62).
Remarkably, Loeber et al. have underpinned factors related to
these conflicting results. The authors have provided evidence
that group differences in inhibitory control were moderated
by the interaction of restrained eating and mood (63). In
addition, the higher commission errors related to food stimuli
performed by the BED group occurred when individuals
were restrained eaters and in a very positive mood at the
time of testing, which, somehow, might explain why our
study did not observe deficits in the Go/No-go task among
groups (63).
Our findings could contribute to expanding the
comprehension of the pathophysiological substrates of BED,
suggesting dysfunction of GABAergic inhibitory interneurons
in prefrontal cortices since cumulative TMS studies provided
evidence that CSP is influenced by the inhibitory function of
cortical or subcortical structures (64). Despite the contribution
of our results in the comprehension of changes in measures
related to neuroplasticity in the two disorders, the correlational
nature does not allow a causality relationship.
This study presents some limitations: First, TMS consists
of an indirect neurophysiological measure intended to assess
the activity of a neurotransmitter system. Though we have
properly chosen ISI, it is important to point out that even
if SICI at 2ms and ICF at 12ms resulted in normal BED, it
does not allow stating its normality at other ISIs, since the
paired-pulse paradigm typically provides a stimulus–response
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TABLE 3 | Primary outcome—multivariate linear regression model of the cortical excitability measures indexed by the CSP, SICI, and ICR according to groups of eating
disorder (n = 59).
(A) Main effects
Dependent Variables Type III Sum of Squares df Mean Square F P Partial Eta Squared
Corrected model
Short intracortical inhibition [(SICI, ratio: SICI/test stimulus)] 10.017a 8 1.25 0.66 0.722 0.10
Cortical Silent period [(CSP, ratio: CSP/test stimulus)] 7,825.86b 8 978.23 2.35 0.031 0.27
Intracortical facilitation [(ICF), ratio: ICF/test stimulus] 15.44c 8 1.93 0.48 0.858 0.07
(B) Beta coefficients
B SEM t P 95% CI
Primary outcome
Dependent variable: Cortical Silent Period [(CSP), ratio: CSP/test stimulus]
Intercept 111.381 28.590 3.896 <0.001 (53.95 to 168.80)
Obese 17.533 11.948 1.467 0.149 (−6.47 to 41.53)
Healthy controls −3.306 8.205 −0.403 0.689 (−19.79 to 13.17)
Ex-obese 0 reference
Binge Eating Disorder 42.480 13.151 3.230 0.002 (16.06 to 68.90)
Use of psychotropic medication −8.805 10.412 −0.846 0.402 (−29.71 to 12.10)
Secondary outcome
Dependent variable: Short intracortical inhibition [(SICI), ratio: SICI/test stimulus]
Intercept −0.360 1.927 −0.187 0.853 (−4.23 to 3.51)
Obese 0.381 0.805 0.474 0.638 (−1.24 to 2.00)
Healthy controls −0.217 0.553 −0.393 0.696 (−1.33 to 0.89)
Ex obese 0 reference
Binge Eating Disorder −0.001 0.886 −0.002 0.999 (−1.78 to 1.78)
Use of psychotropic medication −0.810 0.702 −1.155 0.254 (−2.22 to 0.60)
Dependent variable: Intracortical facilitation [(ICF), ratio: ICF/ test stimulus]
Intercept −0.169 2.783 −0.061 0.952 (−5.76 to 5.42)
Obese −2.169 1.163 −1.865 0.068 (−4.50 to 0.17)
Healthy controls −0.409 0.799 −0.512 0.611 (−2.01 to 1.19)
Ex obese 0 reference
Binge Eating Disorder −2.010 1.280 −1.570 0.123 (−4.58 to 0.56)
Use of psychotropic medication −0.701 1.014 −0.692 0.492 (−2.74 to 1.33)
aR2 = 0.96 (Adjusted R2 = −0.049).
bR2 = 0.273 (Adjusted R2 = 0.157).
cR2 = 0.073 (Adjusted R2 = −0.076).
curve of intracortical excitability at different ISIs for both
inhibition (e.g., 2, 3, and 5ms) and facilitation (e.g., 10, 12,
and 15ms). In line with that, it must be considered that we
have chosen a protocol to elicit CSP during a muscle activity
settled to approximately 20% of the maximal force, and not to
∼50% as recommended, and that can explain the variability of
responses between studies. However, we believe that setting 20%
of the maximal force could provide a more accurate measure
of GABA-mediated excitability of inhibitory neural circuits, as
recently described (65). Second, psychiatric disorders remain a
potential confounding factor, especially because both severity
of depressive symptomatology and poor sleep quality, which
are frequently comorbid conditions found in BED patients,
may have affected the findings, since both of them can alter
cortical excitability, including CSP length (66, 67). On the other
hand, it is important to point out that we have controlled the
analysis for these potentially confounding variables, including
anxiety levels, depressive symptoms, eating psychopathology,
and psychiatric diagnosis. Third, we must address the effect
of psychotropic medicines under cortical excitability because
the regular prescription of these medicines deliberates the
proper treatment of BED. Nevertheless, it is critical to mention
that different changes in cortical excitability produced using
psychotropic medications might produce distinctive outcomes
in acute and long-term use. Fourth, GABAB neurophysiological
deficits may be closely related to the pathophysiology of major
depressive disorder (MDD), which is a frequent comorbid
disorder in individuals with BED, and in a clinical study, we
cannot dissociate these conditions, which are comorbidly and
closely related with BED. Therefore, the difference among groups
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TABLE 4 | Multivariate linear regression model of the cortical inhibition and eating psychopathology according to clinical and non-clinical groups (n = 59).
(A) Main effects
Dependent variables Type III Sum of Squares df Mean Square F P Partial Eta Squared
Corrected model
Cortical Silent Period 5,803.158e 5 1,160.632 2.727 0.029 0.208
Binge Eating Scale 2,628.373a 5 525.675 20.105 <0.001 0.659
Global Score—Eating Disorder Examination Questionnaire 44.151b 5 8.830 14.342 <0.001 0.580
Commission errors neutral 13.409c 5 2.682 0.965 0.448 0.085
Commission errors food 23.836d 5 4.767 1.950 0.102 0.158
(B) Beta coefficients
B SEM t P 95% CI
Primary outcome
Dependent variable: Cortical Silent Period [(CSP), ratio: CSP/test stimulus]
Intercept 96.618 7.316 13.206 <0.001 81.93 to 111.29
Healthy controls 0.635 8.282 0.077 0.939 −15.98 to 11.25
Obese 2.082 7.626 0.273 0.786 −13.22 to 17.38
Binge Eating Disorder 25.702 9.491 2.708 0.009 6.65 to 44.75
Ex-obese 0a . . . .
Beck Depression Inventory 0.130 0.330 0.394 0.695 −0.53 to 0.79
Pittsburgh Sleep Quality Index −0.435 0.463 −0.940 0.351 −1.34 to 0.49
Secondary outcome
Dependent variable: Binge Eating Scale
Intercept 6.298 1.813 3.473 0.001 2.66 to 9.94
Healthy controls −3.332 2.053 −1.623 0.111 −7.45 to 0.79
Obese −0.432 1.890 −0.229 0.820 −4.22 to 3.36
Binge Eating Disorder 7.011 2.352 2.980 0.004 2.29 to 11.73
Ex-obese 0a . . . .
Beck Depression Inventory 0.308 0.082 3.760 <0.001 0.14 to 0.37
Pittsburgh Sleep Quality Index 0.137 0.115 1.192 0.239 −0.09 to 0.37
Dependent variable: Global score Eating Disorder Examination Questionnaire
Intercept 1.085 0.278 3.899 <0.001 0.52 to 1.64
Healthy controls −0.756 0.315 −2.400 0.020 −1.38 to −0.12
Obese −0.054 0.290 −0.187 0.852 −0.63 to 0.53
Binge Eating Disorder 0.107 0.361 0.297 0.768 −0.61 to 0.83
Ex-obese 0a . . . .
Beck Depression Inventory 0.067 0.013 5.307 <0.001 0.04 to 0.09
Pittsburgh Sleep Quality Index 0.000 0.018 0.024 0.981 −0.03 to 0.04
Dependent variable: Commission errors neutral
Intercept 2.993 0.591 5.063 <0.001 1.80 to 4.17
Healthy controls −1.018 0.669 −1.521 0.134 −2.36 to 0.33
Obese 0.149 0.616 0.243 0.809 −1.08 to 1.39
Binge Eating Disorder 0.411 0.767 0.536 0.594 −1.128 to 1.95
Ex-obese 0a . . . .
Beck Depression Inventory −0.003 0.027 −0.115 0.909 −0.06 to 0.05
Pittsburgh Sleep Quality Index −0.024 0.037 −0.631 0.531 −0.09 to 0.05
Dependent variable: Commission errors food
Intercept 1.958 0.554 3.530 0.001 0.84 to 3.07
Healthy controls −0.866 0.628 −1.380 0.174 −2.12 to 0.39
Obese −0.182 0.578 −0.314 0.755 −1.34 to 0.98
Binge Eating Disorder 0.032 0.719 0.044 0.965 −1.41 to 1.48
Ex-obese 0a . . . .
Beck Depression Inventory −0.044 0.025 −1.746 0.087 −0.09 to.007
Pittsburgh Sleep Quality Index 0.079 0.035 2.239 0.029 0.008 to 0.15
aR2 = 0.659 (Adjusted R2 = 0.626).
bR2 =0.580 (Adjusted R2 = 0.539).
cR2 =0.085 (Adjusted R2 = − 0.003).
dR2 =0.158 (Adjusted R2 = 0.077).
eR2 =0.208 (Adjusted R2 = 0.132).
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FIGURE 3 | Pearson’s correlation analysis among CSP, eating behavior, and inhibitory control through the Go/No-Go paradigm. Scatter plots of CSP, eating behavior,
and Go/No-Go paradigm (n = 60). BES, Binge Eating Scale; CSP, cortical silent period; BDI-II, Beck Depression Inventory; PSQI, Pittsburgh Sleep Quality Index;
EDE-Q, Eating Disorder Examination Questionnaire. The CSP was positively correlated with BES (A), Eating Concern (B) and BDI-II (C), while the BES was positively
correlated to BDI-II (D) and PSQI (E). BDI-II was positively associated with the EDE-Q global score (F).
in depressive symptoms could constitute a confounding factor in
the relationship between CSP and BED. However, it is essential to
emphasize that we carefully included in the analysis the potential
confounders related to each dependent variable analyzed, such as
psychiatric diagnosis and depressive symptoms.
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